Ocugen, Inc/$OCGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ticker
$OCGN
Sector
Primary listing
Employees
116
Headquarters
Website
Ocugen, Inc Metrics
BasicAdvanced
$420m
-
-$0.23
2.21
-
Price and volume
Market cap
$420m
Beta
2.21
52-week high
$2.73
52-week low
$0.90
Average daily volume
6.6m
Financial strength
Current ratio
1.862
Quick ratio
1.538
Long term debt to equity
472.713
Total debt to equity
573.575
Interest coverage (TTM)
-12.62%
Profitability
EBITDA (TTM)
-64.177
Gross margin (TTM)
-828.91%
Net profit margin (TTM)
-1,605.22%
Operating margin (TTM)
-1,483.85%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-68.24%
Return on equity (TTM)
-660.00%
Valuation
Price to revenue (TTM)
85.341
Price to book
72.27
Price to tangible book (TTM)
72.27
Price to free cash flow (TTM)
-6.433
Free cash flow yield (TTM)
-15.55%
Free cash flow per share (TTM)
-0.193
Growth
Revenue change (TTM)
-1.26%
Earnings per share change (TTM)
13.45%
3-year revenue growth (CAGR)
15.06%
3-year earnings per share growth (CAGR)
-16.14%
What the Analysts think about Ocugen, Inc
Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.
Ocugen, Inc Financial Performance
Revenues and expenses
Ocugen, Inc Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs